- Analytics
- Trading News
Trading News
Target Tries to Win Back Customers With Back to School Deals
Target has had a tough year. In its Q1 2025 earnings report store sales dropped 3.8% compared to last year. Even though digital sales rose by 4.7%, fewer people are visiting stores. Foot traffic fell 4.8%...
The Musk vs Trump Feud Is Theater
In recent months, headlines have been buzzing with claims of a “feud” between Elon Musk and Donald Trump. Trump calls Musk “bullshit.” Musk says Trump should “sail into the sunset.” Journalists...
Netflix Stock Analysis: Insider Selling, Technical Patterns…
Netflix stock analysis reveals insider selling, key chart patterns, and updated 2025 forecast. Should you buy NFLX now? Read before you trade. Netflix: Insider Selling Raises Questions Multiple Netflix...
Boeing 737 MAX Hits 38 Jets Per Month| Latest 2025 Update
After Years of Turmoil, Boeing Reaches FAA Production Limit. Boeing has produced 38 737 MAX jets in May 2025 — the first time it's met that production cap since late 2020. This milestone signals a potential...
Why Is Netflix Stock Going Up? | Latest 2025 Update
Netflix stock is on the rise, and many investors are asking the same question: why is Netflix going up? The answer lies in strong earnings, smart business moves, and big changes in how Netflix makes money....
Trump vs Walmart
Key Point: growing clash between politics and retail margins could spell new volatility for consumer stocks—and potential inflation surprises. Over the weekend, Trump publicly attacked Walmart for planning...
Skechers Sells Out at a Discount—3G Capital Buys the Panic
Skechers is undervalued, and 3G Capital knows it. In a surprise move, Skechers has agreed to go private in a $9.42 billion buyout led by 3G Capital. The deal, valued at $63 a share, represents a 28% premium...
Tesla Posts One of Worst Quarters Since 2022
Automotive revenue, which has always been Tesla’s main driver, fell 20% year over year. They sold 337,000 cars, down 13%, and that’s after price cuts have already hurt their margins. Not only are Teslas...
How to Trade JNJ: Stelara Decline and New Product Hopes
Johnson & Johnson (JNJ) drug Stelara, which brought in more than $11 billion last year, is under threat from biosimilars in both the U.S. and Europe. Which directly hits JNJ’s core pharma revenue and...
Explore our
Trading Conditions
- Spreads from 0.0 pip
- 30,000+ Trading Instruments
- Instant Execution
Ready to Trade?
Open Account